Twice daily gefapixant 45 mg was associated with a clinically meaningful reduction in cough frequency in patients with chronic cough.
Use of the COPD case-finding tool, CAPTURE, in US primary care practice demonstrated ability to provide critical in-study information to help guide protocol adjustment based on unforeseen events and to clearly outline COPD diagnostic processes.
Early identification if interstitial lung disease (ILD), followed by subsequent tocilizumab therapy initiation, may preserve lung function in patients with systemic sclerosis-associated ILD.
The novel ORACLE scale (Oxford Asthma Attack Risk Scale) demonstrated potential to predict — and subsequently prevent — asthma attacks using biomarkers of type 2 airway inflammation.
Use of vasoactive intestinal peptide to treat critical COVID-19 respiratory failure in patients with comorbidities has shown promise.
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Both dual bronchodilation and triple therapy demonstrated similar rates of mortality in patients with moderate to severe COPD at low risk for exacerbations.